Sickle cell bone disease and response to intravenous bisphosphonates in children.

C Grimbly P Diaz EscagedoJ L JaremkoAisha A Bruce Nathalie Alos Marie-Ève RobinsonV N KonjiM PageM ScharkeEwurabena A SimpsonY D PastoreR GirgisRobert Todd AlexanderL M Ward

Published in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2022)

Children with SCD have the potential for extensive and early-onset bone morbidity. In this series, IV bisphosphonates were effective for bone pain analgesia and did not trigger sickle cell complications.

Keyphrases

early onset
bone mineral density
young adults
late onset
soft tissue
pain management
bone loss
bone regeneration
chronic pain
risk factors
risk assessment
human health